Is MoonLake Immunotherapeutics (NASDAQ: MLTX) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

MLTX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $57.02 and fluctuated between $60.76 as its day high and $55.57 as its day low. The current market capitalization of MoonLake Immunotherapeutics is $3.42B. A total of 0.62 million shares were traded on the day, compared to an average of 658.36K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, MLTX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 31 BUYs and 0 SELLs from insiders. Insiders purchased 802,051 shares during that period but sold 0.

In the most recent transaction, Bodenstedt Matthias sold 5,264 shares of MLTX for 58.34 per share on Dec 20. After the transaction, the Chief Financial Officer now owns 520,903 company shares. In a previous transaction on Dec 19, Bodenstedt Matthias sold 94,736 shares at 59.22 per share. MLTX shares that Chief Financial Officer owns now total 526,167.

Among the insiders who bought shares, Chen Bihua acquired of 58,839 shares on Oct 05 at a per-share price of $59.90. This resulted in the 10% Owner holding 8,494,151 shares of MLTX after the transaction. In another insider transaction, Chen Bihua bought 67,814 shares at $57.32 per share on Oct 04. Company shares held by the 10% Owner now total 8,435,312.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, MLTX has a high of $63.78 and a low of $11.61.

As of this writing, MLTX has an earnings estimate of -$0.23 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of -$0.15 per share and a lower estimate of -$0.37. The company reported an EPS of -$0.23 in the last quarter, which was 14.80% higher than expectations of -$0.27.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MLTX’s latest balance sheet shows that the firm has $8.04M in Cash & Short Term Investments as of fiscal 2021. There were $15.00M in debt and $21.09M in liabilities at the time. Its Book Value Per Share was $7.93, while its Total Shareholder’s Equity was -$11.65M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MLTX is Buy with a score of 4.77.

Most Popular

Related Posts